Nebenwirkungen · Bortezomib Sun
Bortezomib SUN 3.5 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 22
HOS-223672 · Präparat HOS-217212
Notable differences in the safety profile of bortezomib administered subcutaneously versus intravenously as single agent In the Phase III study patients who received bortezomib subcutaneously compared to intravenous administration had 13% lower overall incidence of treatment emergent adverse reactions that were Grade 3 or higher in toxicity, and a 5% lower incidence of discontinuation of bortezomib. The overall incidence of diarrhoea, gastrointestinal and abdominal pain, asthenic conditions, upper respiratory tract infections and peripheral neuropathies were 12%-15% lower in the subcutaneous group than in the intravenous group. In addition, the incidence of Grade 3 or higher peripheral neuropathies was 10% lower, and the discontinuation rate due to peripheral neuropathies 8% lower for the subcutaneous group as compared to the intravenous group.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-14T13:00:00Z · SHA-256 189d5c64096c6ce843ae2899cc1dd9eccab22375c329b68685aafd0f812f3937 · Passage 03ce1e4829100b59e2bcfc66956eab9d4be26321f8ad7de2f5b760ba359d8ee1 · Zeichen 32647–33503 im Abschnitt